AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19144144 — intervention group
Group type: EXPERIMENTAL
Intervention: Children living in households with lower economic or education levels
Number of subjects: 3354
Study 19144144 — intervention group
Group type: EXPERIMENTAL
Intervention: Children living near the hydrographic network
Number of subjects: 3354
Study 19144144 — intervention group
Group type: EXPERIMENTAL
Intervention: Children living in sparsely built-up areas
Number of subjects: 3354
Study 19144144 — intervention group
Group type: EXPERIMENTAL
Intervention: Children living in irregularly built areas
Number of subjects: 3354
Study 19144144 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who did not use a bed net
Number of subjects: 3354
Study 19144144 — intervention group
Group type: EXPERIMENTAL
Intervention: Children sampled during the rainy season
Number of subjects: 3354
Study 19144144 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who had traveled outside of Ouagadougou
Number of subjects: 3354
Study 19144144 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of CSP-antibodies during dry season
Number of subjects: 3354
Study 19144144 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of P. falciparum infections during dry season
Number of subjects: 3354
Study 19144144 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of CSP-antibodies during rainy season
Number of subjects: 3354
Study 19144144 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of P. falciparum infections during rainy season
Number of subjects: 3354
Study 17920972 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at true points
Number of subjects: 32
Study 17920972 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 32
Study 15491083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-brushing done once a day before breakfast (phase 1)
Number of subjects: 20
Study 15491083 — intervention group
Group type: COMPARATOR
Intervention: Twice daily mouthrinsing with 0.2% sodium fluoride (phase 2)
Number of subjects: 20
Study 15491083 — intervention group
Group type: COMPARATOR
Intervention: Twice daily mouthrinsing with 0.03% triclosan and 0.05% sodium fluoride (phase 3)
Number of subjects: 20
Study 15491083 — intervention group
Group type: COMPARATOR
Intervention: Twice daily mouthrinsing with 0.2% chlorhexidine (phase 4)
Number of subjects: 20
Study 11296177 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth pressure during sniff maneuver (Pmosn)
Number of subjects: 30
Study 11296177 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal inspiratory pressure (MIP)
Number of subjects: 30
Study 9762666 — intervention group
Group type: COMPARATOR
Intervention: T cell receptor V beta 5 analysis in MS patients (8 patients)
Number of subjects: 17
Study 9762666 — intervention group
Group type: COMPARATOR
Intervention: T cell receptor V beta 17 analysis in MS patients (8 patients)
Number of subjects: 17
Study 7816001 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g elemental calcium/day (n = 9)
Number of subjects: 18
Study 7816001 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 18
Study 2454615 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPM (cyclophosphamide, adriamycin, cisplatin, mitomycin C)
Number of subjects: 167
Study 2454615 — intervention group
Group type: COMPARATOR
Intervention: MCT (mitomycin C, cytosine arabinoside, tegafur)
Number of subjects: 167
Study 2454615 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP (cisplatin, adriamycin, peplomycin)
Number of subjects: 167
Study 2454615 — intervention group
Group type: COMPARATOR
Intervention: MCTTT (mitomycin C, cyclophosphamide, tespamine, toyomycin, tegafur)
Number of subjects: 167
Study 31713464 — intervention group
Group type: EXPERIMENTAL
Intervention: PEER intervention
Number of subjects: 41
Study 31713464 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 41
Study 30419966 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous stimulation at 10 kHz
Number of subjects: 11
Study 30419966 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous stimulation at 5 kHz
Number of subjects: 11
Study 30419966 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study 28586588 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of bupivacaine plus methylprednisolone
Number of subjects: 109
Study 28586588 — intervention group
Group type: COMPARATOR
Intervention: Epidural injection of bupivacaine only
Number of subjects: 109
Study 24703286 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-tapping miniscrews (35 patients, 70 screws)
Number of subjects: 70
Study 24703286 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-drilling miniscrews (35 patients, 70 screws)
Number of subjects: 70
Study 24703286 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-drilling miniscrews with root contact
Number of subjects: 70
Study 24703286 — intervention group
Group type: COMPARATOR
Intervention: Self-tapping miniscrews with no root contact
Number of subjects: 70
Study 22653618 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation with a telehealth monitoring device for four months
Number of subjects: 111
Study 22653618 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 111
Study 20363901 — intervention group
Group type: EXPERIMENTAL
Intervention: Think framing
Number of subjects: 0
Study 20363901 — intervention group
Group type: EXPERIMENTAL
Intervention: Feel framing
Number of subjects: 0
Study 20363901 — intervention group
Group type: COMPARATOR
Intervention: Cognitive orientation priming
Number of subjects: 0
Study 20363901 — intervention group
Group type: COMPARATOR
Intervention: Affective orientation priming
Number of subjects: 0
Study 20363901 — intervention group
Group type: COMPARATOR
Intervention: Processing fluency mediation
Number of subjects: 0
Study 18841082 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-second rest interval
Number of subjects: 36
Study 18841082 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second rest interval
Number of subjects: 36
Study 18841082 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-second rest interval
Number of subjects: 36
Study 18841082 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second rest interval for older women
Number of subjects: 36
Study 18841082 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 exercise-to-rest ratio for knee flexor recovery in older women
Number of subjects: 36
Study 15513491 — intervention group
Group type: EXPERIMENTAL
Intervention: WizAir-DVT device
Number of subjects: 50
Study 15513491 — intervention group
Group type: COMPARATOR
Intervention: Kendall SCD
Number of subjects: 50
Study 11229421 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 32
Study 11229421 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-diabetic women)
Number of subjects: 32
Study 9505748 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + lignocaine 0.1 mg.kg‐1
Number of subjects: 0
Study 9505748 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + lignocaine 0.2 mg.kg‐1
Number of subjects: 0
Study 9505748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold propofol
Number of subjects: 0
Study 9505748 — intervention group
Group type: COMPARATOR
Intervention: Propofol premixed with normal saline (control group)
Number of subjects: 0
Study 8002056 — intervention group
Group type: EXPERIMENTAL
Intervention: Megaloblastic anemia patients
Number of subjects: 31
Study 8002056 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study 8002056 — intervention group
Group type: EXPERIMENTAL
Intervention: Megaloblastic anemia patients after correction of anemia
Number of subjects: 31
Study 3292250 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine-supplemented formula (480 mumol/l)
Number of subjects: 20
Study 3292250 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk formula without taurine
Number of subjects: 20
Study 29681228 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving
Number of subjects: 20
Study 29681228 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus driving
Number of subjects: 20
Study 29681228 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 28838846 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CTA)
Number of subjects: 9470
Study 28838846 — intervention group
Group type: COMPARATOR
Intervention: Functional testing (nuclear stress testing)
Number of subjects: 9470
Study 25386668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CoQ10 (200 mg/day) plus NADH (20 mg/day) supplementation
Number of subjects: 73
Study 23333369 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 34713
Study 23333369 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 34713
Study 23333369 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 34713
Study 23333369 — intervention group
Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 34713
Study 21395643 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofluoroalkane formulation of budesonide (800 µg twice daily)
Number of subjects: 0
Study 21395643 — intervention group
Group type: COMPARATOR
Intervention: Chlorofluorocarbon formulation of budesonide (800 µg twice daily)
Number of subjects: 0
Study 21395643 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofluoroalkane formulation of budesonide (200 µg followed by 800 µg for 4 weeks)
Number of subjects: 0
Study 21395643 — intervention group
Group type: COMPARATOR
Intervention: Chlorofluorocarbon formulation of budesonide (200 µg followed by 800 µg for 4 weeks)
Number of subjects: 0
Study 18693327 — intervention group
Group type: EXPERIMENTAL
Intervention: Per cycle analysis of treatment
Number of subjects: 0
Study 18693327 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of randomized women analysis
Number of subjects: 0
Study 16492275 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain inserted during forearm closing (Group I, n = 40)
Number of subjects: 80
Study 16492275 — intervention group
Group type: COMPARATOR
Intervention: No drain used (Group II, n = 40)
Number of subjects: 80
Study 12582975 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 27
Study 12582975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12582975 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam vs. Placebo
Number of subjects: 27
Study 10852601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) in combination with cyclosporine (CsA) and prednisone (Pred)
Number of subjects: 184
Study 10852601 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) and prednisone (Pred)
Number of subjects: 184
Study 9085014 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial hyperresponsiveness defined as the provocative dose causing a 20% fall in FEV1
Number of subjects: 931
Study 9085014 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial hyperresponsiveness defined as a 10% fall in FEV1
Number of subjects: 931
Study 9085014 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial hyperresponsiveness defined using corresponding cut‐off values of the linear dose‐response slopes of the percent decline in FEV1 (DRS)
Number of subjects: 931
Study 9085014 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression analyses of various transformations of the DRS
Number of subjects: 931
Study 9085014 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocally transformed DRS
Number of subjects: 931
Study 8449396 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Halon 1301 (bromotrifluoromethane, CBrF3)
Number of subjects: 8
Study 8449396 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 8
Study 3953986 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08% bupivacaine (Group A)
Number of subjects: 53
Study 3953986 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine (Group B)
Number of subjects: 53
Study 31332835 — intervention group
Group type: EXPERIMENTAL
Intervention: Block bone substitute (DBBM)
Number of subjects: 24
Study 31332835 — intervention group
Group type: COMPARATOR
Intervention: Particulate bone substitute (DBBM)
Number of subjects: 24
Study 30239757 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg daily
Number of subjects: 0
Study 30239757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25970741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention or metformin
Number of subjects: 1816
Study 25443696 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 1619
Study 25443696 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1619
Study 25443696 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 1619
Study 22678095 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniYAG (small low-energy Nd:YAG capsulotomy)
Number of subjects: 25
Study 22678095 — intervention group
Group type: COMPARATOR
Intervention: GentleYAG (low-energy Nd:YAG laser treatment without opening the lens capsule)
Number of subjects: 25
Study 20032276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 387
Study 20032276 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 387
Study 18783071 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical sphincterotomy
Number of subjects: 70
Study 18783071 — intervention group
Group type: COMPARATOR
Intervention: 0.2% glyceryl trinitrate ointment
Number of subjects: 70
Study 15087961 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine patient‐controlled analgesia with presurgical bupivacaine sciatic nerve blockade
Number of subjects: 30
Study 15087961 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine patient‐controlled analgesia with postsurgical bupivacaine sciatic nerve blockade
Number of subjects: 30
Study 15087961 — intervention group
Group type: COMPARATOR
Intervention: Morphine patient‐controlled analgesia alone
Number of subjects: 30
Study 11033402 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar anesthesia
Number of subjects: 16
Study 11033402 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia
Number of subjects: 16
Study 11033402 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study 9323470 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenic bacteremic patients
Number of subjects: 123
Study 9323470 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteremic patients
Number of subjects: 123
Study 9323470 — intervention group
Group type: COMPARATOR
Intervention: Non-bacteremic patients
Number of subjects: 123
Study 8418020 — intervention group
Group type: EXPERIMENTAL
Intervention: maxEPA 20 g/day
Number of subjects: 9
Study 8418020 — intervention group
Group type: EXPERIMENTAL
Intervention: maxEPA 10 g/day
Number of subjects: 9
Study 8418020 — intervention group
Group type: EXPERIMENTAL
Intervention: maxEPA 5 g/day
Number of subjects: 9
Study 8418020 — intervention group
Group type: COMPARATOR
Intervention: Placebo 20 g/day
Number of subjects: 9
Study 3535967 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole single perioperative prophylactic dose of 2 g
Number of subjects: 20
Study 3535967 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole treatment course of 8 g over 7 days
Number of subjects: 20
Study 30503704 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver relief after the death of a family member with dementia (FaCTS)
Number of subjects: 312
Study 30503704 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparedness for care recipient's (CR's) death
Number of subjects: 312
Study 30503704 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of CR's death as a relief
Number of subjects: 312
Study 30503704 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater CG relief
Number of subjects: 312
Study 30503704 — intervention group
Group type: EXPERIMENTAL
Intervention: CG relief
Number of subjects: 312
Study 29058596 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Hydrogen (2% hydrogen with 24% to 50% oxygen) for 18 hours after admission via mechanical ventilation
Number of subjects: 360
Study 29058596 — intervention group
Group type: COMPARATOR
Intervention: Control group (24% to 50% oxygen) for 18 hours after admission via mechanical ventilation
Number of subjects: 360
Study 25619692 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with open reduction and internal fixation (ORIF)
Number of subjects: 76
Study 25619692 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 76
Study 23324076 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival processing scenario
Number of subjects: 0
Study 23324076 — intervention group
Group type: COMPARATOR
Intervention: Moving to a new house
Number of subjects: 0
Study 22935858 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature mud pack
Number of subjects: 27
Study 22935858 — intervention group
Group type: COMPARATOR
Intervention: Hot pack
Number of subjects: 27
Study 18926614 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT Dual Cure + Calibra (non-thermocycled)
Number of subjects: 160
Study 18926614 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond All-in-One Dual Cure + Nexus 2 (non-thermocycled)
Number of subjects: 160
Study 18926614 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno IV Dual Cure + Calibra (thermocycled)
Number of subjects: 160
Study 18926614 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus Dual Cure + Nexus 2 (non-thermocycled)
Number of subjects: 160
Study 17971007 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel dressing (moist wound healing)
Number of subjects: 160
Study 17971007 — intervention group
Group type: COMPARATOR
Intervention: Mepore dressing (standard care)
Number of subjects: 160
Study 14999522 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg risedronate administered in the morning under fasting condition without breakfast
Number of subjects: 0
Study 14999522 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg risedronate administered 30 min before breakfast
Number of subjects: 0
Study 14999522 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg risedronate administered 30 min after breakfast
Number of subjects: 0
Study 14999522 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg risedronate administered 3 h after breakfast
Number of subjects: 0
Study 11153450 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical multiple synovectomy (RaMS) with continued pre-operative medication (group A)
Number of subjects: 67
Study 11153450 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with DMARDs after RaMS (group B)
Number of subjects: 67
Study 11153450 — intervention group
Group type: COMPARATOR
Intervention: No surgery, combination therapy with DMARDs (group C - control)
Number of subjects: 67
Study 9104689 — intervention group
Group type: EXPERIMENTAL
Intervention: Late night partial sleep deprivation (LSD)
Number of subjects: 41
Study 9104689 — intervention group
Group type: EXPERIMENTAL
Intervention: Early night partial sleep deprivation (ESD)
Number of subjects: 41
Study 9104689 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery sleep after ESD (ESD-R)
Number of subjects: 41
Study 9104689 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery sleep after LSD (LSD-R)
Number of subjects: 41
Study 9104689 — intervention group
Group type: COMPARATOR
Intervention: Baseline late luteal phase
Number of subjects: 41
Study 8253222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium eye drops (2%)
Number of subjects: 45
Study 8253222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 3515925 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of oral flurbiprofen
Number of subjects: 161
Study 3515925 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of intramuscular morphine sulfate
Number of subjects: 161
Study 3515925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 30714095 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive randomization schemes
Number of subjects: 3
Study 30714095 — intervention group
Group type: COMPARATOR
Intervention: Naïve z-test
Number of subjects: 3
Study 29446699 — intervention group
Group type: EXPERIMENTAL
Intervention: d-cycloserine (250 mg)
Number of subjects: 38
Study 29446699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 26615713 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin split-thickness skin grafts (STSGs)
Number of subjects: 192
Study 26615713 — intervention group
Group type: COMPARATOR
Intervention: Occlusive hydrocellular dressing (Control Group B)
Number of subjects: 192
Study 26615713 — intervention group
Group type: COMPARATOR
Intervention: Paraffin gauze (Control Group C)
Number of subjects: 192
Study 25851453 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea, arginine and carnosine cream (UC)
Number of subjects: 50
Study 25851453 — intervention group
Group type: COMPARATOR
Intervention: Glycerin-based emollient cream (SEC)
Number of subjects: 50
Study 23865124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 70
Study 23865124 — intervention group
Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 70
Study 21091788 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐UCA (0%, 0.02%, 0.2%, or 2%)
Number of subjects: 40
Study 21091788 — intervention group
Group type: COMPARATOR
Intervention: 0% C‐UCA (placebo)
Number of subjects: 40
Study 19146155 — intervention group
Group type: EXPERIMENTAL
Intervention: Dingweiban manipulation
Number of subjects: 122
Study 19146155 — intervention group
Group type: COMPARATOR
Intervention: Xieban manipulation
Number of subjects: 122
Study 16602365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 25
Study 16602365 — intervention group
Group type: COMPARATOR
Intervention: Resilient telescopic crowns
Number of subjects: 25
Study 14686724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP)
Number of subjects: 111
Study 14686724 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol-electrolyte (PEG-EL)
Number of subjects: 111